The global cystic fibrosis drugs market is expected to witness more than 10% CAGR to touch approximately $10 billion by 2025

Bangalore, India, August 02, 2019: With its recently published study “Global Cystic Fibrosis Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025”, Infoholic Research forecasts that the global market for cystic fibrosis drugs is expected to witness mid-single-digit growth during the forecast period 2019–2025. It is observed that more than 30,000 people are affected by cystic fibrosis (CF) in the US and globally the number touches to more than 70,000. Approximately 1,000 new cases of cystic fibrosis are registered every year. Restoration of CFTR function, mucociliary clearance, anti-inflammation, and anti-infective agents are the therapeutic approaches used in the development of effective drugs for CF.

Access Full Report Summary @ https://www.infoholicresearch.com/report/cystic-fibrosis-drugs-market

Ireland has the most cystic fibrosis prevalence worldwide – around 1 out of 19 individuals in Ireland carry one copy of a mutated gene that can cause cystic fibrosis. A study conducted to analyze the prevalence of cystic fibrosis in Europe by 2025 has shown that the number of patients suffering from this condition is likely to increase by approximately 50%. The percentage of CF adults will rise by about 75%, mostly when children step to the adolescent stage, whereas the number of CF children will rise by 20%.

Get a sample copy of the report @ https://www.infoholicresearch.com/request-a-sample-report/?repid=14473

Pharmaceutical companies are working on various routes of administration for better absorption of the drugs. Recently Horizon Pharma USA, Inc. in collaboration with Forest Laboratories has completed the phase III double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin administered as MP-376 given for 28 days by the aerosol route to CF patients.

“The market for cystic fibrosis drugs is dominated by Vertex Pharmaceuticals with their orkambi, kalydeco, and symdeko products. Recent information published by Proteostasis in March 2019 for its proprietary triple combination drug PTI-NC-733 (PTI-428/PTI-801/PTI-808) expressed concerns as to whether Proteostasis would contest Vertex's grip on the CFTR modulator place.” pointed out Rikitha K Murthy, Senior Research Analyst, Infoholic Research

Key Segments of the Report include:

• Drug Class:
  • CFTR Modulators
  • Mucolytics
  • Bronchodilators
  • Pancreatic Enzyme Supplements
  • Others
• Route of Administration:
  • Oral
  • Inhalation
  • Intravenous
• Regions:
  • North America
  • Europe
  • APAC
  • RoW
• Industry outlook: Market trends, drivers, restraints, and opportunities

Contact: Ms. Kathakali Basu

Infoholic Research LLP

ND: 080-461-51400

USA: 1-661-210-1186

kathakali@infoholicresearch.com